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Abstract
Background: Naturally acquired immune responses against sexual stages of P. falciparum can reduce the transmission of
malaria from humans to mosquitoes. These antigens are candidate transmission-blocking vaccines but little is known about
the acquisition of sexual stage immunity after exposure to gametocytes, or their longevity and functionality. We conducted
a longitudinal study on functional sexual stage immune responses.
Methodology/Principal Findings: Parasitaemic individuals (n = 116) were recruited at a health centre in Lower Moshi,
Tanzania. Patients presented with gametocytes (n = 16), developed circulating gametocytes by day 7 (n = 69) or between
day 7 and 14 (n = 10) after treatment or did not develop gametocytes (n = 21). Serum samples were collected on the first day
of gametocytaemia and 28 and 84 days post-enrolment (or d7, 28, 84 after enrolment from gametocyte-negative
individuals). Antibody responses to sexual stage antigens Pfs230 and Pfs48/45 were detected in 20.7% (72/348) and 15.2%
(53/348) of the samples, respectively, and were less prevalent than antibodies against asexual stage antigens MSP-119
(48.1%; 137/285) and AMA-1 (52.4%; 129/246)(p,0.001). The prevalence of anti-Pfs230 (p = 0.026) and anti-Pfs48/45
antibodies (p = 0.017) increased with longer duration of gametocyte exposure and had an estimated half-life of
approximately 3 months. Membrane feeding experiments demonstrated a strong association between the prevalence and
concentration of Pfs230 and Pfs48/45 antibodies and transmission reducing activity (TRA, p,0.01).
Conclusions/Significance: In a longitudinal study, anti-Pfs230 and Pf48/45 antibodies developed rapidly after exposure to
gametocytes and were strongly associated with transmission-reducing activity. Our data indicate that the extent of antigen
exposure is important in eliciting functional transmission-reducing immune responses.
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Introduction
Recent successes in eliciting transmission-reducing immune
responses with malaria transmission-blocking vaccines (MTBV) in
animal models [1,2,3,4] have fuelled interest in future deployment
of these vaccines as part of malaria control and elimination
strategies [5,6]. Understanding the dynamics of naturally acquired
transmission reducing immune responses will assist in the future
deployment of MTBV in endemic populations. The transmission
of malaria depends on the presence of mature sexual stage
parasites, gametocytes, in the human peripheral blood. Once
ingested by a mosquito taking a blood meal, gametocytes will form
male microgametes and female macrogametes that after fertiliza-
tion and zygote formation develop into ookinetes that penetrate
the mosquito midgut wall to form an oocyst underneath the basal
lamina of the midgut. Each oocyst produces thousands of
sporozoites, rendering the mosquito infectious to humans. The
infectiousness of gametocytes to mosquitoes depends on their
density [7,8,9] and level of maturation [10] but also on mosquito
[11] and human immune responses [12]. Human transmission-
reducing antibodies are ingested by Anopheline mosquitoes
together with gametocytes and can interfere with zygote formation
and, as a consequence, further development of parasites in the
mosquito vector. MTBV are designed to induce such antibody
responses to reduce the infectiousness of gametocytes to mosqui-
toes or even block transmission completely [6,13,14].
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The three most promising MTBV candidates for Plasmodium
falciparum so far are based on the induction of antibody responses
against parasite antigens Pfs230, Pfs48/45 and Pfs25 [1,2,3,4,15].
Pfs48/45 and Pfs230 are expressed on the surface of gametes and
are involved in the fertilization of macrogametocytes by
microgametes [5]; Pfs25 is a postfertilisation antigen expressed
on the surface of ookinetes [4], and plays a role in the traversal of
the mosquito midgut epithelium [16]. The gamete surface
molecules Pfs48/45 and Pfs230 are also expressed in gametocytes
circulating in the human blood and antibody responses against
these antigens are detected in naturally exposed individuals
[12,17,18]. This makes it possible to study the nature and
duration of sexual-stage specific immunity in naturally infected
individuals [5]. Naturally acquired sexual stage-specific antibody
responses may be acquired after exposure to gametocytes [12] and
rapidly induced as part of the initial response to infection [19,20].
In contrast to antibodies against pre-erythrocytic and blood-stage
antigens [19,21,22], the prevalence of sexual-stage specific
antibodies does not increase with age [23,24]. Little is known
about the rate of induction or longevity of sexual-stage antibody
responses and this may be important for natural boosting of any
vaccine induced response.
Here, we determine the acquisition, longevity and functionality
of sexual stage specific antibody responses in a longitudinal study
in an area of low endemicity in Tanzania.
Methods
Ethics permission was received from the ethical committees of
the National Institute for Medical Research, the Kilimanjaro
Christian Medical Centre, and the London School of Hygiene and
Tropical Medicine. Written consent was obtained from all
participants or their parents/guardians prior to enrolment in the
study.
Individuals were recruited from January 2003 till December
2004 at the health centre in Msitu wa Tembo and the clinic of the
nearby sugar plantation, Tanzania Plantation Company, in Lower
Moshi (latitude 3u 339 S; longitude 37u 179 E). The area of Lower
Moshi lies at an altitude of ,700 meters between the Maasai
savannah and foothills of Mount Kilimanjaro. Malaria transmis-
sion at the time the study was conducted was hypoendemic with an
estimated entomologic inoculation rate of 3.4 (95% CI 0.7–9.9)
infectious bites per person per year [25] and peaks in malaria
incidence following the rains in March–May and October–
November. The low level of malaria transmission was considered
to be beneficial for the current study objectives because of the low
likelihood of re-infections during follow-up. Individuals were
eligible for recruitment if they were found parasitaemic after
examination of 100 high power microscopic fields. Slides were
read for asexual parasites and gametocytes separately, each by two
technicians. Asexual parasites and gametocytes were enumerated
against 200 and 500 leukocytes, respectively, and expressed as
density/mL assuming an average leukocyte count of 8,000/mL.
Parasitaemic individuals were treated with sulphadoxine-pyri-
methamine (SP) according to national guidelines at that time and
seen on day 7, 14, 28, 42, 56 and 84 after initiation of treatment.
On days 7, 14, 28, and 84, a slide was taken to determine exposure
to asexual parasites and gametocytes; a rapid diagnostic test
[ParacheckH, Orchid Biomedical Systems, India] was used to
detect infection qualitatively on day 42 and 56. On the first day of
gametocytaemia and on days 28 and 84 after enrolment, a venous
blood sample was taken for serological analyses and standard
membrane feeding assay. Samples were also taken from indi-
viduals who did not present with microscopically detectable
gametocytes in the 28 days post treatment. For these individuals,
sampling was done on day 7, 28 and 84 after enrolment. This
observational study was exploratory in nature and no formal
sample size calculation was done.
Enzyme-linked immunosorbent assays (ELISAs)
Antigen preparation. Mature gametocytes of P. falciparum
(NF54 strain) were produced in an automated static culture system
[26], isolated on 63% Percoll [no. 17-0891-01, GE Healthcare,
Uppsala, Sweden] and stored at 270uC until used. The NF54
gametocytes were extracted in 25 mM Tris-HCl, pH 8.0, supple-
mented with 150 mM NaCl, 1.0% sodium desoxycholate, and
1 mM phenylmethylsulfonyl fluoride. Samples were centrifuged at
13,0006g for 5 minutes at room temperature to remove insoluble
debris and the supernatant was used as the source of whole
parasite antigen.
ELISA for sexual stage antigens Pfs230 and Pfs48/
45. The presence of human antibodies to Pfs48/45 and Pfs230
was determined by a two-site ELISA as described previously [19].
Briefly, 96-well microtiter plates (Sterilin-ELISA plates [no. 53011;
International Medical Products B.V., Zutphen, The Netherlands]
were coated with anti-Pfs230 mouse monoclonal antibody (MAb)
63F2A2 (5 mg/mL) in phosphate-buffered saline (PBS), pH 7.4. For
Pfs48/45, the plates were coated with rat MAb 85RF45.3. Free sites
were blocked with 5% low-fat dry milk [Marvel, Premier
International Foods Ltd., Spalding, United Kingdom] in PBS.
Pfs48/45 and Pfs230 were captured from a gametocyte extract
(250,000 parasite equivalents/well) for half of the wells; the other
half was tested without antigen. Serum samples (1: 100 dilution)
were added to the wells and incubated for two hours. Bound IgG
antibodies were detected by horseradish peroxidase–labeled goat
anti-human IgG [31412; Pierce Biotechnology, Inc., Rockford, IL].
The wells were washed three times with PBS and subsequently
incubated with tetramethylbenzidine substrate (TMB) solution for
20 minutes. The colour reaction was stopped with 2 NH2SO4, and
optical density (OD) was read at 450 nm [Anthos 2001 microplate
reader; Labtec BV, Heerhugowaard, The Netherlands]. All
incubations were carried out at room temperature. All serum
samples were tested in duplicate with a concurrent positive control
and a minimum of four negative (Dutch blood bank donor) controls
per plate. The OD was adjusted for background reactivity by
subtracting the OD without antigen.
ELISA for asexual stage antigens Apical Membrane
Antigen-1 (AMA-1) and Merozoite Surface Protein-119
(MSP-119). Anti-MSP-119 and anti-AMA-1 human IgG anti-
bodies were detected by ELISA using standard methodology
[21,27], using the sera at 1/1000 and 1/2000 dilution,
respectively. The OD was standardized against a positive control
that was included on each plate.
For sexual and asexual stage ELISAs, all samples from one
individual were included on the same plate; a cut-off above which
samples were deemed antibody positive was defined using a
mixture model as previously described [27]. The distribution of
OD values was subsequently fitted as the sum of two Gaussian
distributions (a narrow distribution of sero-negatives and a broader
distribution of sero-positives) using maximum likelihood methods.
The mean OD of the Gaussian corresponding to the sero-negative
population plus three standard deviations was used as the cut-off
for sero-positivity.
Standard membrane feeding assay (SMFA)
Twenty-five individuals were selected for membrane feeding
experiments. The selection was done randomly; the only selection
criterion was the availability of a complete set of three serum
Anti-Gametocyte Antibodies
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e14114
samples from the first day of patent gametocytaemia, day 28 and
day 84after enrolment. Seventy-five serum samples from these 25
individuals were purified for the SMFA using the Protein G HP
Multitrap [GE Healthcare, Uppsala, Sweden: Code no 28-9031-
35] according to the manufacturer’s instructions. 200mL plasma
was diluted with 400ml binding buffer and added in triplicate to the
96-well plate. The flow through (FT) still contains antibody and
can be isolated using the same procedure twice. The eluted and
neutralized samples were combined, diluted to 20ml with MilliQ
water and subsequently concentrated to the original starting
volume using centrifugal concentration tubes [Vivaspin 20,
Sartorius AG, Goettingen, Germany: Code no VS2021]. The
purified field samples were used for testing in the ELISAs, or
added to freeze dried FCS (90ml) tubes for testing in the membrane
feeding assay. The yield of protein varied from 2 to 4 mg/ml and a
mean recovery of 76.2% (standard deviation of 13.9%) varied
between 51% and 97%.
Experimental infections of mosquitoes were carried out as
previously described [28,29] including samples from the same
individual in the same experiment. Three to five day old A. stephensi
were allowed to feed on cultured P. falciparum gametocytes of
NF54, in the presence of purified control serum or test sample at a
final dilution of 1:3 in the feeder. After feeding, blood-fed
mosquitoes were kept at 26uC. Surviving mosquitoes were
dissected seven days later, and oocyst counts were made for each
sample. Midguts of 20 mosquitoes were examined for oocysts. The
experiment was considered valid when at least 70% of the
mosquitoes feeding on control sera were infected. The observed
transmission reducing activity (TRA) of serum was determined as
the percentage reduction in arithmetic mean oocyst number in test
samples as compared to paired controls [30].
Statistical analysis
Data was double entered in MS Access and imported into
STATA version 11 (StataCorp LP, College Station, TX, USA).
Binary variables were analysed by Chi-square, Fisher’s Exact or
Chi-square test for trend; odds ratio’s with 95% confidence
intervals were presented where appropriate. The association
between continuous variables was determined by the nonpara-
metric Spearman correlation coefficient. To determine the
longevity of the antimalarial antibody responses, we analysed the
change in concentrations of antibodies to Pf230 and Pfs48/45
between day 28 and day 84 in relation to time (in days) since the
last documented exposure to gametocytes (day 0–28). The
longevity of antibody responses to MSP-119 and AMA-1 was
estimated in a similar manner, using the change in antibody
concentration between day 7 and day 84 in relation to time since
the last documented exposure to asexual parasites (day 0). The
half-life of the antibody response was analysed in a repeated
measurements analysis using log-linear regression model including
adjusting for associations between multiple data points from the
same subjects. Half-lives were calculated from the estimated decay
rate and the boundaries at 95% confidence interval obtained from
the mixed-effects model [31]. A curve was fitted for Pfs230 and
Pfs48/45 antibody concentration in relation to the reduction in
oocyst numbers using GraphPad Prism software 4.02 (GraphPad
Software, Inc., CA, USA).
Results
Sexual stage antibody responses were examined in 116
individuals who presented with asexual P. falciparum parasites at
the clinic and who had gametocytes at enrolment (n = 16),
developed gametocytes on day 7 (n = 69) or day 14 (n= 10) after
treatment with SP or did not develop on any day gametocytes after
treatment (n = 21) (table 1). After clearance of the initial infection,
no re-infections were detected during follow-up by microscopic
slide (day 7, 14, 28, 84) or by rapid diagnostic test (day 42, 56).
Anti-Pfs230 antibodies were detected in 20.7% of the samples
(72/348); 25.9% (30/116) of the participants showed Pfs230
seroreactivity on at least one time-point during the study. Anti-
bodies against Pfs48/45 were detected in 15.2% (53/348) of the
samples; 27.6% (32/116) of the participants showed Pfs48/45
seroreactivity on at least one occasion. There was a strong positive
association between the prevalence of gametocytes (p,0.001) and
concentration of antibodies against Pfs230 and Pfs48/45 (Spear-
man correlation coefficient 0.66, p,0.001). Recognition of Pfs230
and Pfs48/45 increased with age in our population (figure 1).
Antibody responses to asexual stage antigens AMA-1 and MSP-119
were detected in 52.4% (129/246) and 48.1% (137/285) of the
samples and antibody prevalence increased with age (figure 1).
The induction and duration of sexual stage antibody
responses
Sexual stage antibody prevalence and concentration were
related to recent cumulative exposure to gametocytes prior to
sampling. There was no statistically significant association between
the duration of gametocyte exposure and Pfs230 antibody
prevalence on day 7 after enrolment (OR 1.74, 95% CI 0.79–
3.87, p = 0.17). Pfs230 antibodies on day 28 after enrolment were
less prevalent in individuals who had no microscopically detectable
gametocytes between day 0 and day 28, more prevalent in those
who had gametocytes on only one occasion during this period (,1
week) and most prevalent in individuals who had gametocytes for
$1 week (trend: OR 2.44, 95% CI 1.11–5.36; p = 0.026). A
similar association was observed for Pfs48/45 antibodies on day 7
(trend: OR 2.62, 95% CI 0.98–7.01, p = 0.054) and on day 28
(OR 2.73, 95% CI 1.19–6.35; p = 0.017) after adjustment for age
(figure 2; table 2). Similarly, an increase in day 28 antibody
concentrations (optical density in the ELISA) for Pfs230 (b=0.12,
95% CI 0.01–0.23, p = 0.046) and Pfs48/45 (b=0.060, 95% CI
0.00–0.12, p = 0.066) was observed across these gametocyte
carriage categories, after adjustment for age (table 2). These
trends disappeared by day 84 for Pfs230 antibody prevalence (OR
Table 1. Demographic information.
Age, median (IQR) 10 (5–18)
Gender, % female 42.1 (48/114)
Asexual parasite density/mL, median (IQR) 133 (34–812)
Proportion presenting with fever ($37.5uC), %(n/N) 56.6 (64/113)
Clinical malaria (parasite density.1000/mL & fever) 11.5% (13/113)
First day of gametocytaemia
Never 18.1 (21/116)
Prior to treatment 13.8 (16/116)
7 days post initiation treatment 59.5 (69/116)
14 days post initiation treatment 8.6 (10/116)
28–84 days post initiation treatment 0.0 (0/116)
Duration of gametocytaemia
,2 weeks 75.0 (69/92)
2–3 weeks 16.3 (15/92)
.3 weeks 8.7 (8/92)
doi:10.1371/journal.pone.0014114.t001
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1.29, 95% CI 0.52–3.20, p= 0.58) and concentration (b=0.051,
95% CI -0.03–0.14, p= 0.24) and for Pfs48/45 antibody
prevalence (OR 1.93, 95% CI 0.46–8.14, p= 0.37) and concen-
tration (b=0.039, 95% CI 0.00–0.08, p = 0.074). Although sexual
stage antibody prevalence was least common in those who did not
develop gametocytes during follow-up (p,0.001), there was a
borderline significant increase in the prevalence of both Pfs230
(p = 0.076) and Pfs48/45 antibodies (p = 0.14) between day 7, 28,
and 84 in this group. There was no association between the
duration of gametocyte exposure and the antibody prevalence or
concentration for AMA-1 (p$0.42) and MSP-119 (p$0.48) on any
of the days of sampling.
The decay of Pfs230 and Pfs48/45 antibody responses was
determined in individuals who had serum samples collected on day
28 and day 84 and who were antibody positive on day 28 without
evidence for continued exposure to gametocytes or re-infection
with asexual parasites after day 28. For Pfs230 antibodies, 60
paired observations were available for 30 individuals and the half-
life of antibody responses was estimated at 92.6 (95% CI 74.7–
122.0) days. This half-life of Pfs230 antibodies appeared shorter in
children below 10 years of age (73.9 days, 95% CI 58.6–99.9)
compared to adults (100.5 days, 95% CI 76.2–147.9) although not
statistically significant (p = 0.10). For Pfs48/45 52 paired observa-
tions were available from 26 individuals and the half-life of
antibody responses was estimated at 83.0 (65.8–112.3) days.
Similarly for Pfs48/45, the half-life of antibody responses
appeared shorter in children below 10 years of age (70.2 days,
95% CI 54.1–100.0) compared to older individuals (90.3 days,
95% CI 65.7–144.0) although not statistically significant (p = 0.25).
The half-lives for Pfs230 and Pfs48/45 antibody responses were
similar to those of responses against AMA-1 (97.7 days, 95% CI
78.6–129.1; based on 140 observations from 52 individuals) and
MSP-119 (52.4 days, 95% CI 44.5–63.6; 145 observations from 52
individuals). AMA-1 and MSP-119 antibody responses declined
gradually after enrolment (p#0.001).
The functionality of sexual stage antibody responses
Seventy five samples from 25 individuals were included in the
SMFA (table 3), giving an overall median reduction of oocyst
numbers of 19.4% (IQR 0–66.7). Of the 25 individuals who were
included in the SMFA, 6 (24%) were consistent responders to
Pfs230 (i.e. Pfs230 antibody positive on all three days), 3 (12%)
consistent responders to Pfs48/45 and 3 (12%) consistently
reduced transmission $50% (TRA$50, table 3). Individuals
who showed TRA$50% on all three occasions were significantly
more likely to be a consistent responder to Pfs48/45 (p= 0.002)
and Pfs230 (p= 0.065), although the latter was not statistically
significant.
When samples were considered individually (n= 75), TRA$50%
was significantly associated with Pfs230 antibody prevalence (OR
13.14; 95% CI 1.90–91.16, p= 0.009 after adjustment for repeated
measures) and Pfs48/45 antibody prevalence (OR 43.04; 95% CI
3.21–577.44, p= 0.005). Twelve samples, derived from six
individuals, reduced oocyst numbers $90% (TRA$90%), 100%
(12/12) of these were positive for Pfs230 antibodies and 91.7% (11/
12) for Pfs48/45 antibodies. We observed a strong positive
association between the reduction in oocyst numbers in the SMFA
and Pfs230 (Spearman correlation coefficient = 0.65, p,0.001) and
Pfs48/45 antibody concentration (Spearman correlation coeffi-
cient = 0.54, p,0.001). Samples with a higher antibody concentra-
tion were more likely to reduce oocyst numbers (figure 3). In a
multivariate model that incorporated reactivity to both antigens,
there was a strong association between the reduction in oocyst
numbers and Pfs230 (b=35.93, 95% CI 22.35–49.51, p,0.001)
and Pfs48/45 antibody concentration (b=44.57, 95% CI 20.49–
68.85, p,0.001). Of all samples with an OD.1 in the Pfs230
ELISA, 83.3% (10/12) showed TRA$90%; 87.5% of the samples
with an OD.0.8 in the Pfs48/45 ELISA showed TRA$90%. All
Figure 2. Pfs230 and Pfs48/45 antibody prevalence in relation
to the duration of exposure to gametocytes during follow-up.
Bars indicate total antibody prevalence in individuals who did not
develop gametocytes during follow-up (clear bars), individuals who had
gametocytes detected by microscopy on only one occasion (shaded
bars, less than one week) and individuals who had gametocytes
detected on at least two consecutive visits that were at least 7 days
apart (filled bars, $1 week); error bars indicate the upper limit of the
95% confidence interval. On day 7 and 28 after enrolment, the number
of observations from individuals without gametocyte exposure was 22,
from individuals with gametocytes ,1 week 69, and from individuals
with gametocytes for $1 week 25. On day 84, these figures were 19, 69
and 25. The asterisks indicates a statistically significant positive trend
between antibody responses and duration of exposure to gametocytes
(p,0.05).
doi:10.1371/journal.pone.0014114.g002
Figure 1. Antibody responses to Pfs230 and Pfs48/45 in
relation to age. Bars indicate antibody prevalence in different age-
groups, error bars the upper limit of the 95% confidence interval.
Multiple observations are included per individual. Antibody responses
to Pfs230 (p = 0.006), Pfs48/45 (p = 0.008), AMA-1 (p,0.001) and MSP-
119 (p = 0.013) increased with increasing age, after adjusting for
correlations between observations from the same individual. The
number of observations for Pfs230, Pfs48/45, AMA-1 and MSP-119 were
69, 69, 31, 32 (,5 years), 168, 168, 134, 134 (5–14 years), 111, 111, 119,
81 ($15 years). The asterisks indicates a statistically significant positive
trend between antibody responses and age in all categories (p,0.05).
doi:10.1371/journal.pone.0014114.g001
Anti-Gametocyte Antibodies
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Table 2. Pfs230 and Pfs48/45 antibody prevalence and concentration in relation to the duration of exposure to gametocytes
during follow-up.
Pfs230 Pfs48/45
Sampling
time-point
Gametocyte exposure
during follow-up
Antibody prevalence,
% (n/N)
Antibody concentration,
median OD (IQR)
Antibody prevalence,
% (n/N)
Antibody concentration,
median OD (IQR)
Day 7 No 9.1 (2/20) 0.09 (0.03–0.14) 0.0 (0/22) 0.07 (0.04–0.15)
,1 week 15.9 (11/69) 0.11 (0.04–0.18) 14.7 (10/69) 0.10 (0.04–0.19)
$1 week 24.0 (6/25) 0.18 (0.08–0.25) 20.0 (5/25) 0.14 (0.06–0.29)
Day 28 No 14.3 (3/21)* 0.15 (0.05–0.18)* 14.3 (3/21)* 0.09 (0.08–0.20)¥
,1 week 21.7 (15/69)* 0.11 (0.04–0.20)* 17.4 (12/69)* 0.10(0.06–0.20)¥
$1 week 44.0 (11/25)* 0.28 (0.11–0.50)* 44.0 (11/25)* 0.25(0.08–0.49)¥
Day 84 No 15.8 (3/19) 0.08 (0.01–0.22) 5.3 (1/19) 0.08 (0.02–0.16)¥
,1 week 15.9 (11/69) 0.08 (0.03–0.18) 5.8 (4/69) 0.07(0.02–0.16)¥
$1 week 24.0 (6/25) 0.16 (0.07–0.29) 12.0 (3/25) 0.16(0.04–0.27)¥
Antibody concentration (optical density, OD, in the ELISA) was adjusted for background reactivity by subtracting the OD without antigen; seropositive and seronegative
individuals are included in the table.
*Trend-test, p,0.05;
¥0.05.p,0.1.
doi:10.1371/journal.pone.0014114.t002
Table 3. Individual data from repeated membrane feeding experiments.
ID Age
First-last day
gametocytes
Pfs230 antibody prevalence
d7-d28-d84
Pfs48/45 antibody
prevalence
d7-d28-d84
TRA$50% and $90%
prevalence
d7-d28-d84
468 32 D0 0-0-0 0-0-0 0-0-0
565 8 D7 0-0-0 0-0-0 0-0-0
842 5 D7 0-0-0 0-0-0 0-0-0
849 10 D7 0-0-0 0-0-0 0-0-0
603 25 D14 0-0-0 0-0-0 0-0-0
649 13 D14 0-1-0 0-0-0 0-0-0
585 5 D7 0-0-0 1-1-0 0-0-0
639 29 D0–28 1-1-1 1-1-0 0-0-0
655 9 D7 1-1-0 1-1-0 0-0-0
724 11 Not detected 1-1-1 0-0-0 0-0-0
554 8 D7 0-0-0 0-0-0 1-0-0
527 8 D7 0-1-1 0-0-0 0-1-0
829 41 D7 0-1-1 1-1-1 0-1-0
886 12 D14–28 1-1-1 0-1-0 0-1-0
910 5 D7 1-1-0 0-0-0 0-1-0
752 10 Not detected 1-1-1 0-0-0 0-1-0
754 12 Not detected 0-0-0 0-1-0 0-1-0
1045 29 Not detected 0-0-0 0-0-1 0-0-1
1049 16 D7–28 0-1-1 0-1-0 0-2-0
579 6 D7 0-0-0 0-1-0 1-1-0
801 12 D0 1-1-0 1-1-0 2-1-0
902 10 D7 0-1-1 0-1-0 0-2-2
596 6 D0–28 0-1-1 0-1-1 1-2-2
889 46 D7 1-1-1 1-1-1 2-2-2
826 41 D14 1-1-1 1-1-1 2-2-2
Data are given for 25 individuals who had samples taken on three time-points: day 7 (d7), day 28 (d28) and day 84 (d84). For Pfs230 and Pfs48/45 seroreactivity:
0 = absence of antibodies; 1 = presence of antibodies. For Transmission Reducing Activity (TRA) in the standard membrane feeding assay: 0 =,50% reduction in the
number of oocysts; 1$50% reduction; 2$90% reduction. Individuals are ranked based on their TRA in the standard membrane feeding assay.
doi:10.1371/journal.pone.0014114.t003
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samples (6/6) that fulfilled both these criteria reduced oocyst
numbers by $90%.
Discussion
In this study, we determined the acquisition, longevity and
effectiveness of antibody responses against P. falciparum sexual stage
antigens Pfs230 and Pfs48/45 in individuals residing in an area of
low endemicity in Tanzania after a recent malaria episode.
Antibody prevalence and concentration were related to the
duration of gametocyte exposure and showed a strong association
with transmission- reducing activity (TRA).
The current study provided longitudinal data on sexual stage
immune responses with repeated assessments of (functional) sexual
stage immune responses shortly after a single malaria episode.
Most previous studies on naturally acquired immune responses to
P. falciparum sexual stage antigens relied on cross-sectional study
designs [17,18,23,32,33,34,35,36,37], making it difficult to deter-
mine factors associated with the induction or persistence of sexual
stage immune responses. To the best of our knowledge, only three
studies have previously determined the acquisition and loss of
sexual stage immune responses in longitudinal settings. These
studies collected samples at 3- or 6-monthly intervals [19,24,38,39]
and suggested that sexual stage antibody responses and functional
TRA can be acquired rapidly [19] and may be more common in
children than adults [23,24,39]. The current study focused on
recently infected individuals and determined exposure to malaria
parasites and immune responses in the weeks following a clinical
episode, i.e. when there are potentially infectious gametocytes
circulating against which transmission reducing immunity can act.
Serological assessments were made at the time of first presentation
with gametocytes and 4 and 12 weeks after enrolment,
corresponding to 2–4 and 10–12 weeks after first presentation
with gametocytes. None of the individuals in our cohort were
re-infected with malaria parasites during 84-day follow-up. The
prevalence and concentration of Pfs230 and Pfs48/45 antibodies
were correlated with a longer duration of recent exposure to
gametocytes. Less than 10% of the individuals who did not
develop microscopically detectable gametocyte concentrations had
antibodies against Pfs230 or Pfs48/45 one week after clearance of
asexual parasitaemia. This proportion of seropositives showed a
non-significant increase over time, which may be the result of
immune-boosting by submicroscopic gametocyte densities that
frequently accompany patent asexual parasite carriage and persist
for several weeks [40,41,42] but were not measured in the current
study. The use of molecular gametocyte detection methods,
unavailable at the time, would have improved our study as some of
the exposure to gametocyte antigens in our cohort will have been
missed due to the limited sensitivity of microscopy for detecting
low density gametocytaemia [9,42,43,44,45]. Submicroscopic
infections were previously associated with the boosting of immune
responses to schizont [46] and merozoite antigens [47] and it is
therefore possible that sub-microscopic gametocyte densities may
have had a similar immune-boosting effect in our study. Because
only microscopy data were available, we were only able to test the
association between exposure to relatively high, i.e. microscopi-
cally detectable, gametocyte densities and sexual stage immunity.
There was a pronounced increase in sexual stage specific antibody
prevalence and concentration in individuals who were exposed to
microscopically detectable gametocyte densities during follow-up:
more than one-third of individuals who carried gametocytes on at
least two occasions during follow-up were positive for Pfs230 and
Pfs48/45 antibodies four weeks after exposure to gametocytes.
Previous studies often found no association between sexual stage
immune responses and concurrent gametocyte prevalence or
density [19,23,24,39], although the association is both biologically
plausible and supported by indirect evidence from literature. For
example, a study using immunoprecipitation for immune respons-
es to Pfs230 and Pfg 27/25 observed variation in the intensity of
bands in relation to malaria exposure, suggestive of immune
boosting during the malaria season [39]. Similarly, Pfs230 and
Pfs48/45 antibody prevalence and concentration increased with
increasing recent exposure to malaria infections in Indonesian
migrants exposed to malaria in hyperendemic Papua [19].
Sexual stage immune responses also increased with age in our
cohort of parasite carriers. This study was not specifically designed
to examine age related acquisition of immune responses and the
sample size is insufficient to disprove observations from previous
studies that showed that sexual stage immune responses do not
increase with age [23,24,39]. However, age may well be a modu-
lating factor in the acquisition or maintenance of sexual stage
immune responses after (recent) exposure to sexual stage antigens.
The prevalence of antibodies against Pfs230 and Pfs48/45 was
higher in adults where they also appeared to have a longer half-
life. More stable sexual stage immune responses in adults were
previously reported in the Gambia [38]. There may be an innate
difference between children and adults in how acquired immune
systems function [48,49], resulting in more efficient immune
response after recent exposure in adults compared to children
[46,50,51]. In addition, higher cumulative exposure may have
resulted in a more stable immune response in adults [38].
In line with other studies, total IgG antibody levels against
MSP-119 and AMA-1 showed a rapid decline over time after
antigen exposure [52,53,54]. This probably reflects the lifespan of
short-lived plasma cells after discontinued antigen exposure [51].
The rapid decline in sexual stage antibody titres after acute
infection appears similar to that observed for antibodies to asexual
stage antigens, suggesting that B cell responses may be regulated in
a similar manner. Studies with much longer follow-up periods are
Figure 3. The relation between transmission reducing activity
and Pfs230 and Pfs48/45 antibody concentration. Transmission
reducing activity is plotted as a continuous variable, the reduction in
oocyst density in mosquitoes, on the Y axis against antibody
concentration (optical density, OD) on the X-axis. Filled diamonds
represent Pfs230 antibody responses; open circles Pfs48/45 antibody
responses. The solid line represents the best fit for the association
between Pfs230 antibody concentration and % oocyst reduction; %
oocyst reduction= 100/1+10((0.697-OD Pfs230)*1.44); R2 = 0.56. The dashed
line the association between Pfs48/45 antibody concentration and %
oocyst reduction: % oocyst reduction = 100/1+10((0.490-OD Pfs48/45)*1.84);
R2 = 0.45.
doi:10.1371/journal.pone.0014114.g003
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needed to determine the longevity of antibody responses from
long-lived plasma cells which may sustain low (but detectable)
titres of antibodies for much longer periods. While the longevity of
antibody responses is similar for sexual and asexual stages, our
data nevertheless indicate clear differences in the kinetics of the
two responses, consistent with differences in the timing of antigen
exposure. Sexual stage immune responses increased in the first
month of follow-up, following gametocyte exposure; asexual stage
immune responses declined after asexual parasites were cleared
and were not associated to gametocyte carriage.
We observed a strong association between the presence and
concentration of sexual stage-specific antibody responses and
functional TRA. Pfs230 antibody-related TRA involves comple-
ment-mediated lysis of gametes [55]; Pfs48/45 antibodies can
inhibit zygote development independent of complement [56].
Serum samples with high reactivity to one or both of these
antigens effectively reduced transmission. The observed associa-
tion between Pfs230 and Pfs48/45 antibody prevalence and TRA
was previously observed in field samples [23,24,34,35] but the
association was particularly strong in the current dataset: 11/12
samples that showed TRA$90% were positive for both Pfs48/45
and Pfs230. The stronger association could be a consequence of
using purified IgG rather than serum in the SMFA experiments,
thereby reducing nonspecific effects of serum proteins. When we
compared antibody concentration data with TRA, the association
suggested a clear lower threshold of antibody concentrations above
which high levels of TRA were assured. This resembles data from
Pfs25/Pvs25 vaccine studies in human volunteers and animal
models where a clear lower threshold could be defined above
which all serum samples reduced transmission by.50% [4,57].
The strength of the association could be partially explained by the
study setting. We recruited individuals who were exposed to
relatively low levels of malaria transmission and may therefore
have less immunity to asexual antigens, which might cross-react
with gametes, reduce their infectivity [58] and thereby confound
the association between sexual stage immune responses and TRA.
The association between sexual stage antibody responses and TRA
may vary between settings [17,18,19,23,24,32,35,59,60]. In our
study population, ,25% of all participants showed reactivity to
Pfs230 or Pfs48/45. This proportion is similar to that found in
gametocyte carriers from Tanzania [23] and Cameroon [17] and
Tanzanian adults exposed to intense transmission intensity [24]
but twofold lower than that reported in Sri Lankan individuals
exposed to low level transmission intensity [60]. This underlines
the necessity of carrying out longitudinal studies in areas with
different transmission characteristics to determine the generality of
our findings and determine whether the strong associations that we
report can be extrapolated to other regions.
In conclusion, our data indicate that antibody responses to
Pfs230 and Pfs48/45 are boosted by recent exposure to
gametocytes and that increased antibody levels are associated
with the duration of carriage of gametocytes. Our predicted half
lives of sexual stage antibodies of 70–90 days are in broad
agreement with the predicted half life of gametocyte carriage of 55
days [40]. However, antibody levels are correlated with TRA and
the low antibody titres observed in the latter stages of infection
may be insufficient to affect gametocyte infectivity of mosquitoes.
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